Overview
Sweden biotech firm's Q1 net sales declined yr/yr, net loss widened
Cash flow from operations negative, liquid funds fell to SEK 456.5 mln
Outlook
Company did not provide specific financial or operational guidance for the current or future periods
Result Drivers
CLINICAL PROGRAM INVESTMENT - Co said it continued to allocate resources to advance BI-1808 and BI-1206 immune-modulatory antibody programs
Company press release: ID:nMFNc04SV1
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
SEK 13.40 mln
Q1 Adjusted EPS
-SEK 1.81
Q1 Net Income
-SEK 119.20 mln
Q1 Adjusted Free Cash Flow
-SEK 132.80 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for BioInvent International AB is SEK90.00, about 317.6% above its April 28 closing price of SEK21.55
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
